234 related articles for article (PubMed ID: 28659174)
21. GPCR48/LGR4 promotes tumorigenesis of prostate cancer via PI3K/Akt signaling pathway.
Liang F; Yue J; Wang J; Zhang L; Fan R; Zhang H; Zhang Q
Med Oncol; 2015 Mar; 32(3):49. PubMed ID: 25636507
[TBL] [Abstract][Full Text] [Related]
22. Imatinib mesylate inhibits androgen-independent PC-3 cell viability, proliferation, migration, and tumor growth by targeting platelet-derived growth factor receptor-α.
Nayeem MJ; Yamamura A; Hayashi H; Muramatsu H; Nakamura K; Sassa N; Sato M
Life Sci; 2022 Jan; 288():120171. PubMed ID: 34822800
[TBL] [Abstract][Full Text] [Related]
23. A novel selenonucleoside suppresses tumor growth by targeting Skp2 degradation in paclitaxel-resistant prostate cancer.
Byun WS; Jin M; Yu J; Kim WK; Song J; Chung HJ; Jeong LS; Lee SK
Biochem Pharmacol; 2018 Dec; 158():84-94. PubMed ID: 30292755
[TBL] [Abstract][Full Text] [Related]
24. Delineation of the GPRC6A receptor signaling pathways using a mammalian cell line stably expressing the receptor.
Jacobsen SE; Nørskov-Lauritsen L; Thomsen AR; Smajilovic S; Wellendorph P; Larsson NH; Lehmann A; Bhatia VK; Bräuner-Osborne H
J Pharmacol Exp Ther; 2013 Nov; 347(2):298-309. PubMed ID: 24008333
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
[TBL] [Abstract][Full Text] [Related]
26. Targeting IκB Kinase β/NF-κB Signaling in Human Prostate Cancer by a Novel IκB Kinase β Inhibitor CmpdA.
Zhang Y; Lapidus RG; Liu P; Choi EY; Adediran S; Hussain A; Wang X; Liu X; Dan HC
Mol Cancer Ther; 2016 Jul; 15(7):1504-14. PubMed ID: 27196761
[TBL] [Abstract][Full Text] [Related]
27. Identifying Signalling Pathways Regulated by GPRC5B in β-Cells by CRISPR-Cas9-Mediated Genome Editing.
Atanes P; Ruz-Maldonado I; Hawkes R; Liu B; Persaud SJ; Amisten S
Cell Physiol Biochem; 2018; 45(2):656-666. PubMed ID: 29408822
[TBL] [Abstract][Full Text] [Related]
28. RNA interference targeting PSCA suppresses primary tumor growth and metastasis formation of human prostate cancer xenografts in SCID mice.
Zhao Z; He J; Kang R; Zhao S; Liu L; Li F
Prostate; 2016 Feb; 76(2):184-98. PubMed ID: 26477693
[TBL] [Abstract][Full Text] [Related]
29. CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer therapy via liposomal-coated compounds.
Kadry MO; Abdel-Megeed RM
PLoS One; 2024; 19(5):e0302264. PubMed ID: 38723038
[TBL] [Abstract][Full Text] [Related]
30. Osteocalcin and Sex Hormone Binding Globulin Compete on a Specific Binding Site of GPRC6A.
De Toni L; Guidolin D; De Filippis V; Tescari S; Strapazzon G; Santa Rocca M; Ferlin A; Plebani M; Foresta C
Endocrinology; 2016 Nov; 157(11):4473-4486. PubMed ID: 27673554
[TBL] [Abstract][Full Text] [Related]
31. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
[TBL] [Abstract][Full Text] [Related]
32. The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia.
García-Tuñón I; Hernández-Sánchez M; Ordoñez JL; Alonso-Pérez V; Álamo-Quijada M; Benito R; Guerrero C; Hernández-Rivas JM; Sánchez-Martín M
Oncotarget; 2017 Apr; 8(16):26027-26040. PubMed ID: 28212528
[TBL] [Abstract][Full Text] [Related]
33. α-santalol inhibits the angiogenesis and growth of human prostate tumor growth by targeting vascular endothelial growth factor receptor 2-mediated AKT/mTOR/P70S6K signaling pathway.
Saraswati S; Kumar S; Alhaider AA
Mol Cancer; 2013 Nov; 12():147. PubMed ID: 24261856
[TBL] [Abstract][Full Text] [Related]
34. ETV4 promotes late development of prostatic intraepithelial neoplasia and cell proliferation through direct and p53-mediated downregulation of p21.
Cosi I; Pellecchia A; De Lorenzo E; Torre E; Sica M; Nesi G; Notaro R; De Angioletti M
J Hematol Oncol; 2020 Aug; 13(1):112. PubMed ID: 32791988
[TBL] [Abstract][Full Text] [Related]
35. CRISPR/Cas9-mediated knockout of Lcn2 effectively enhanced CDDP-induced apoptosis and reduced cell migration capacity of PC3 cells.
Rahimi S; Roushandeh AM; Ebrahimi A; Samadani AA; Kuwahara Y; Roudkenar MH
Life Sci; 2019 Aug; 231():116586. PubMed ID: 31220528
[TBL] [Abstract][Full Text] [Related]
36. [Knocking-out of HIF1α gene by CRISPR/cas9 inhibits proliferation and invasiveness of prostate cancer DU145 cells].
Xu Y; Xu M; Zhang M; Tan J; Su Z; Chen X; Zhou Q
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2018 Apr; 35(2):160-164. PubMed ID: 29652983
[TBL] [Abstract][Full Text] [Related]
37. An enhanced hTERT promoter-driven CRISPR/Cas9 system selectively inhibits the progression of bladder cancer cells.
Huang X; Zhuang C; Zhuang C; Xiong T; Li Y; Gui Y
Mol Biosyst; 2017 Aug; 13(9):1713-1721. PubMed ID: 28702647
[TBL] [Abstract][Full Text] [Related]
38. Impaired osteoblast function in GPRC6A null mice.
Pi M; Zhang L; Lei SF; Huang MZ; Zhu W; Zhang J; Shen H; Deng HW; Quarles LD
J Bone Miner Res; 2010 May; 25(5):1092-102. PubMed ID: 19874200
[TBL] [Abstract][Full Text] [Related]
39. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.
Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171
[TBL] [Abstract][Full Text] [Related]
40. CRISPR/Cas9 targeting of the androgen receptor suppresses the growth of LNCaP human prostate cancer cells.
Wei C; Wang F; Liu W; Zhao W; Yang Y; Li K; Xiao L; Shen J
Mol Med Rep; 2018 Feb; 17(2):2901-2906. PubMed ID: 29257308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
